DKCM
VRDN icon

Davidson Kempner Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Davidson Kempner Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-23,857
Closed -$366K – 291
2023
Q3 		$366K Buy
+23,857
New +$455K ﹤0.01% 159

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Davidson Kempner Capital Management's VRDN Position: Q4 2023 in Review

Davidson Kempner Capital Management sold out of Viridian Therapeutics (VRDN) in Q4 2023, closing a stake of 23,857 shares — an estimated $366K sold.

Davidson Kempner Capital Management first reported a position in VRDN in Q3 2023 and held it in 1 quarter. The position peaked at $366K in Q3 2023. 132 funds tracked by Wall St. Rank hold VRDN as of Q4 2023.

  • Davidson Kempner Capital Management reported no remaining Viridian Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Davidson Kempner Capital Management sold 23,857 Viridian Therapeutics shares in Q4 2023, an estimated $366K.
  • Davidson Kempner Capital Management first reported a position in Viridian Therapeutics in Q3 2023 and held it in 1 quarter.
  • Davidson Kempner Capital Management's Viridian Therapeutics position peaked at $366K in Q3 2023.
  • 132 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2023.

Based on Davidson Kempner Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.